Form 4: Karyopharm Exec Reports PSU Vesting & Tax Sale

Karyopharm Therapeutics' EVP & Chief Commercial Officer, Sohanya Cheng, reported the vesting of performance-based restricted stock units and a subsequent tax-related stock sale.

Summary

• Sohanya Cheng, Executive Vice President and Chief Commercial Officer of Karyopharm Therapeutics Inc. (KPTI), reported recent stock transactions.
• On September 12, 2025, 945 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted in February 2023 and earned based on the achievement of a clinical milestone: complete enrollment in the company's Phase 3 SENTRY trial, as certified by the Compensation Committee.
• On September 15, 2025, 325 shares of common stock were sold at a price of $6.43 per share.
• This sale was non-discretionary, executed under a Rule 10b5-1 plan adopted on June 7, 2022, specifically to satisfy tax withholding liabilities incurred upon the PSU vesting.
• Following these transactions, Sohanya Cheng beneficially owns 35,856 shares of Karyopharm Therapeutics common stock.
• The reported beneficial ownership also includes 922 shares acquired under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

Sentiment

Score: 7

Explanation: The vesting of performance-based restricted stock units due to the achievement of a clinical milestone (Phase 3 SENTRY trial enrollment) is a positive indicator of company progress. The subsequent sale was non-discretionary for tax purposes, which is a neutral event in terms of company performance or executive sentiment.

Positives

• The vesting of performance-based restricted stock units indicates the achievement of a significant clinical milestone, specifically the complete enrollment in the Phase 3 SENTRY trial, demonstrating progress in the company's clinical development pipeline.

Negatives

• A portion of shares (325) was sold, which, while for tax purposes and non-discretionary, reduces the executive's direct equity holding.

Future Outlook

The vesting of performance-based restricted stock units is tied to the achievement of a clinical milestone, specifically the complete enrollment in the company's Phase 3 SENTRY trial, indicating ongoing progress in its clinical development pipeline.

Management Comments

• The sale of 325 shares was effected pursuant to a durable automatic sale instruction plan adopted on June 7, 2022, and represents a broker-assisted sale to satisfy withholding tax liability incurred upon PSU vesting, not a discretionary trade.

Industry Context

This is a routine insider transaction report for an executive in the biotechnology sector. The compensation structure, involving performance-based restricted stock units tied to clinical milestones, is common in the biotech and pharmaceutical industries, aligning executive incentives with research and development progress. The use of a Rule 10b5-1 plan for tax-related sales is also a standard practice for managing executive equity compensation.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) tied to clinical milestones is a common executive compensation practice within the biotechnology and pharmaceutical industries, aligning executive incentives with R&D progress.
• The execution of a Rule 10b5-1 plan for tax-related sales is a standard corporate governance practice for insiders to manage equity compensation in a pre-arranged, non-discretionary manner, similar to practices observed at comparable biotech firms.

Stakeholder Impact

• Shareholders: The achievement of a clinical milestone (Phase 3 SENTRY trial enrollment) could be viewed positively, indicating progress in the company's pipeline. The executive's compensation structure aligns their interests with company performance.
• Employees: The report reflects standard executive compensation practices, including equity awards and employee stock purchase plans.

Key Dates

Recommendation

This Form 4 reports routine insider transactions related to executive compensation and a non-discretionary tax sale. While the underlying clinical milestone achievement is positive, the filing itself does not provide new material information to warrant a change in investment recommendation. It confirms ongoing operations and standard executive compensation practices.

Keywords

Karyopharm Therapeutics, KPTI, Sohanya Cheng, Form 4, Insider Transaction, Executive Compensation, Performance Stock Units, PSU, SENTRY Trial, Clinical Milestone, Rule 10b5-1 Plan, Stock Sale, Tax Withholding